• EnglishEnglish
    • Deutsch Deutsch
    • Italiano Italiano
    • Français Français
    • 日本語 日本語
    • 한국어 한국어

CISEMA - China Zertifizierung, Einkauf und Qualitätssicherung

  • Services
    • NMPA Registration – Medical Devices and IVDs
    • NMPA Registration & DMF – Pharmaceuticals
    • NMPA Registration – Cosmetics
    • NMPA Registration – Health Food
    • CML (China Manufacture Licence) – Pressure vessels
    • CCC (China Compulsory Certification) – Industrial and consumer goods
    • Others
      • Sourcing and Quality Control
      • Logistics and Customs Support
      • Sales Support
  • Events
    • Trade Fairs & Conferences
    • Seminars
    • Webinars
  • News & Knowledge
    • Regulatory News
      • Medical Devices and IVDs
      • Cosmetics
      • Pharmaceuticals & DMF
      • CCC
      • Pressure Vessels
    • Whitepapers
    • FAQ – NMPA Registration – Medical Devices and IVDs
    • Newsletter Sign Up
    • Others
      • Publications
      • Online Shop
  • About us
    • Partners
    • Company Profile
    • Testimonials
  • Locations
  • Newsletter Sign Up
Contact
  • Home
  • News
  • News
  • NMPA Registration in China
  • Medical Device
  • Medical device QMS audit guidelines for product registration are open for comment

Medical device QMS audit guidelines for product registration are open for comment

medical device qms audit
Tuesday, 21 June 2022 / Published in Medical Device, News, NMPA Registration in China

Medical device QMS audit guidelines for product registration are open for comment

China’s NMPA has issued draft guidelines on medical device QMS audit for product registration. The draft Guideline for Inspection of Quality Management System for Medical Device Registration (Revision Draft for Comments) is open for comments by industry stakeholders until June 27, 2022.

This draft is a revision to the 2020 version.  

Scope of Application

This guideline applies to the on-site audit of the Quality Management System (QMS) for Class II and Class III medical device registration carried out by the regulatory authorities.

Key Points on the On-site Audit

  • Quality Management System principle
  • Institution & people
  • Plant, facilities and equipment
  • File management
  • Design and development
  • Procurement
  • Production
  • Quality control
  • Commissioned production
  • Product authenticity

Noteworthy Points

Research and development

For the situation of entrusted research and development (R&D), the applicant should have quality management measures for related activities. The applicant should sign a commissioned R&D agreement with the entrusted R&D institution, clearly stipulating the responsibilities of all parties, the content of R&D and related technical matters. The applicant should be responsible for the process and results of the commissioned R&D, as well as ensuring the reliability of data in the commissioned R&D process. The entrusted institution should comply with the requirements of the agreement to ensure that the R&D process is standardized, and that the data is true, accurate and traceable.

It is worth highlighting that the Guideline once promulgated will, for the first time, provide legal basis for commissioned R&D.

Commissioned production

Where there is a situation of entrustment in the process of R&D or production, the applicant should clarify the departments and personnel responsible for guiding and supervising the quality management system of the entrusted enterprises. Applicants should:

  • trace and monitor the whole process of R&D, production, storage and transportation as well as adverse event monitoring,
  • maintain the continuous improvement of the quality management system,
  • and implement the supervision of the entrusted enterprises.

Checklist of medical device QMS inspection items

A list of inspection items can be found in the appendix to the Guidelines. There are a total of 73 inspection items, of which 32 are key items and 41 are general items. The on-site audit team will make conclusions of “conformed”, “non-conformed” or “non-applicable” to each items separately.

How to submit comments on the medical device QMS audit for product registration guidelines

The deadline for comments is June 27, 2022. Cisema customers may submit their comments to their respective regulatory affairs project manager otherwise comments may be sent directly to mdgmp@cfdi.org.cn, and the subject of the email should be marked as “Comments on the Revision Draft of the Guideline for Inspection of Quality Management System for Medical Device Registration “.

By Grace and Victoria. If you require assistance in establishing a China conform medical device QMS or our registration and CRO services for pharmaceuticals, medical devices, IVDs, cosmetics, health foods, industrial or consumer goods, contact Cisema.

GET IN TOUCH

🌐 Send us your enquiry
📚 Request our whitepapers
📣 Sign up for our newsletter

What you can read next

New NMPA Classification Catalogue for Medical Devices
Inspection report of Jiangxi Meilin Kangda Pharmaceutical in China
Inspection report of Jiangxi Meilin Kangda Pharmaceutical in China
China Export Requirements for Coronavirus Protection Supplies

Search

Categories

  • Fairs & Events
  • News
    • CCC
    • CEL
    • CML, SELO
    • Medical Devices Listing in Hong Kong
    • NMPA Registration in China
      • Cosmetics
      • Health Food
      • Medical Device
      • Pharmaceuticals & DMF
    • RoHS
    • Voluntary Product Certification
  • Publications
  • Seminars
  • Uncategorized
  • Webinars

Recent Posts

  • laser therapy devices

    Clinical evaluation of laser therapy devices – New guidelines issued

    Clinical evaluation of laser therapy devices ha...
  • dental implant system

    Clinical evaluation of dental implant systems in China – New guidelines issued

    Clinical evaluation of dental implant system ha...
  • China Medical Device Webinar

    China Medical Device Webinar with AdvaMed Accel for U.S. exporters

    The China Medical Device Webinar will be featur...
  • webinar_medical-device-market-authorisation

    Cisema presenting at FORUM Institut: Medical device marketing authorisation for advanced – Masterclass China

    Cisema is delighted to hold a Masterclass with ...
  • generative AI services

    China’s generative AI interim measures now in effect

    China’s generative AI interim measures fo...

Archive

Cisema

With twelve locations and over ninety highly qualified employees, Cisema can offer you optimal support in China.

Services

  • Certification
  • Sourcing and Quality Control
  • Logistics and Customs Support
  • Sales Support

Dialogue

  • Contact us
  • Newsletter Signup
  • Events
  • News & Knowledge
  • Partners

Company

  • GTC
  • Privacy Statement
  • Legal Notice
  • About us
  • Locations
  • GET SOCIAL

© 2021 Cisema. All rights reserved.

TOP